Immunohistochemical prognostic factors, qualifying constructs and determinant adverse events in overall survival in invasive breast carcinomas

Abstract

Immunohistochemical prognosis factors or moleculars and qualifying constructs were evaluated  for the contribution to overall survival, and adverse events. It was defined a nonrandom sample of 373 women with invasive breast carcinomas operated on a 15-year period (1992-2007). Results: From the evaluated factors the most contributed to overall survival were the p53 with seven patients (three deaths and 57.1% survival to the value 2 +) and 20 cases (five deaths and 75.0% overall survival for the value 3 +); the Bcl2 gene with 47 patients -13 died and 72.3% survival rate for the zero value and 40 cases (five deaths and 87.5% survival rate for the value 1 +); Top Nottingham prognostic index of 5.4 with 91 patients Nottingham greater forecasting 5.4 with 91 patients -38 died, 69.7% overall survival and an average of 9.33 years, stage IV according to the classification  TNMp with a female patient -who died, with an average of 1.49 years, followe by the stage IIIC with 31 patients -21 of them dead, 32.3% survival and an average of 4.68 years, the N3 component with 32 patients -22 died, 31.3% overall survival and an average of 4.58 years; the M1component with a female patient -who died, with an average of 1.49 years, local recurrence with 17 patients –nine of them died, 47.1% survival and an average of 9.57 years, and distant metastases with 51 patients - 59 dead, with an overall survival of 13.6% and an average of 5.16 years. Conclusion: p53 positive values and negative ​​of Bcl-2, the largest group prognosis of 5.4, stages IV and III C, N3 and M1 components, local recurrence and distant metastases were most influenced in overall survival.